| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a synthetic intermediate, 6-chloro-7-iodo-7-deazapurine does not have specific biological receptors as its primary targets. The 7-deazapurine core is a key structural motif in medicinal chemistry, often used to synthesize compounds that interact with kinases, nucleic acid polymerases, and other enzymes involved in cellular proliferation and viral replication. Derivatives of this scaffold have been explored as potential anticancer and antiviral agents by interfering with nucleic acid metabolism. The compound's halogen substituents (chlorine and iodine) enable further functionalization for structure-activity relationship studies in drug discovery.
|
|---|---|
| ln Vitro |
6-Chloro-7-iodo-7-deazapurine is employed as an intermediary in pharmaceuticals.
In vitro, 6-chloro-7-iodo-7-deazapurine functions primarily as a chemical reagent and building block rather than a direct pharmacological agent. It is employed as an intermediate in the synthesis of various pharmaceutical compounds. The compound's halogenated deazapurine structure allows it to participate in cross-coupling reactions (e.g., Suzuki-Miyaura, Sonogashira) to introduce diverse substituents, enabling the construction of compound libraries for biological screening. The resulting derivatives can exhibit activities against various cancer cell lines and viral targets. Cellular assays are typically performed on the final compounds synthesized from this intermediate. |
| ln Vivo |
In vivo data for 6-chloro-7-iodo-7-deazapurine as a standalone compound is limited, as it is primarily used as a research reagent and synthetic intermediate. The compound is classified for research use only and is not intended for human or veterinary applications. However, pharmaceutical compounds synthesized using this 7-deazapurine scaffold have been investigated for their therapeutic potential in oncology and infectious diseases. The deazapurine core is a privileged structure in drug discovery, and its derivatives have shown promise in preclinical models. Specific in vivo data for the parent compound is not available in the public literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 6-chloro-7-iodo-7-deazapurine are not typically performed, as it is a synthetic intermediate. The compound is used as a building block in the synthesis of kinase inhibitors or other bioactive molecules. A typical assay involves using the compound in chemical reactions (e.g., palladium-catalyzed cross-coupling) to prepare final compounds. The compound is dissolved in organic solvents such as DMSO or THF. Enzyme inhibition assays with purified kinases or other targets can be performed to evaluate the activity of the final synthesized compounds. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for 6-chloro-7-iodo-7-deazapurine are not standard, as the compound is primarily a synthetic intermediate. The compound is used in the preparation of nucleoside analogs and other bioactive molecules. A typical protocol for evaluating the anticancer activity of derivatives involves culturing cancer cell lines (e.g., HeLa, MCF-7, A549) in growth medium at 37°C with 5% CO₂. Cells are treated with synthesized compounds at varying concentrations for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or SRB assays. IC₅₀ values are calculated from dose-response curves. Apoptosis and cell cycle analysis can be performed using flow cytometry.
|
| Animal Protocol |
In vivo animal studies for 6-chloro-7-iodo-7-deazapurine are not standard, as it is a synthetic intermediate rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would typically be conducted on the final pharmaceutical products synthesized using this building block rather than on the building block itself. The compound's primary value lies in its use as a synthetic intermediate for preparing compounds that may subsequently be evaluated in animal models of cancer or infectious diseases.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 6-chloro-7-iodo-7-deazapurine is limited, as it is primarily a synthetic intermediate. The compound has a molecular weight of 279.47 g/mol and a molecular formula of C₆H₃ClIN₃. It is a solid at room temperature and is stored in a cool, dark place, preferably below 15°C. The compound is insoluble in water and has a pKa of 9.61±0.20. As a halogenated deazapurine, it may undergo metabolic dehalogenation and oxidation. Specific ADME data is not available in the public literature.
|
| Toxicity/Toxicokinetics |
6-Chloro-7-iodo-7-deazapurine is classified as a harmful substance (Xn) with risk statements R22 (harmful if swallowed) and R36/37/38 (irritating to eyes, respiratory system, and skin). It causes skin and serious eye irritation. Safety precautions include handling with appropriate personal protective equipment (gloves, eye protection, face protection) and washing thoroughly after handling. The compound should be stored in a sealed, dry container at room temperature, away from light. Acute toxicity data is limited, though it is classified as harmful if swallowed.
|
| Additional Infomation |
6-Chloro-7-iodo-7-deazapurine (CAS 123148-78-7) is a biochemical reagent and pharmaceutical intermediate with the molecular formula C₆H₃ClIN₃. It is also known as 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine. The compound has a melting point of 200.0-204.0°C and a maximum absorption wavelength of 305 nm in water. It is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. The compound is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent.
|
| Molecular Formula |
C6H3CLIN3
|
|---|---|
| Molecular Weight |
279.47
|
| Exact Mass |
278.906
|
| CAS # |
123148-78-7
|
| PubChem CID |
14809281
|
| Appearance |
Off-white to gray solid powder
|
| Density |
2.3±0.1 g/cm3
|
| Melting Point |
179-183ºC
|
| Index of Refraction |
1.804
|
| LogP |
2.06
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
157
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=NC=NC2=C1C(=C[NH]2)I
|
| InChi Key |
CBWBJFJMNBPWAL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H3ClIN3/c7-5-4-3(8)1-9-6(4)11-2-10-5/h1-2H,(H,9,10,11)
|
| Chemical Name |
4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5782 mL | 17.8910 mL | 35.7820 mL | |
| 5 mM | 0.7156 mL | 3.5782 mL | 7.1564 mL | |
| 10 mM | 0.3578 mL | 1.7891 mL | 3.5782 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
